Recent trends in the treatment of unresectable stage III non-small-cell lung cancer.
Aged
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Cisplatin
/ administration & dosage
Clinical Trials as Topic
Combined Modality Therapy
/ trends
Humans
Interdisciplinary Communication
Ipilimumab
/ administration & dosage
Lung Neoplasms
/ diagnosis
Neoplasm Staging
Nivolumab
/ administration & dosage
Patient Care Team
Treatment Outcome
Chemoradiotherapy
Durvalumab
Immune checkpoint inhibitor
Lung cancer
Stage III
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
05
11
2018
revised:
03
03
2019
accepted:
13
03
2019
pubmed:
20
4
2019
medline:
15
1
2020
entrez:
20
4
2019
Statut:
ppublish
Résumé
Approximately 20-25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.
Identifiants
pubmed: 31000495
pii: S2212-5345(18)30244-2
doi: 10.1016/j.resinv.2019.03.004
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Ipilimumab
0
durvalumab
28X28X9OKV
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-336Informations de copyright
Copyright © 2019. Published by Elsevier B.V.